MedTrace Logo

Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease

NCT07338331 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-08-13

No results posted yet for this study

Summary

Non-alcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common hepatic manifestation of metabolic dysfunction and may progress from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.

This randomized clinical trial evaluated and compared three pharmacological approaches with different mechanisms of action: low-dose aspirin as an anti-inflammatory and antiplatelet therapy, dapagliflozin as a sodium-glucose cotransporter-2 (SGLT2) inhibitor with metabolic effects, and metformin as an insulin-sensitizing therapy.

The study assessed their effects on liver enzymes, lipid profile, and FibroScan-derived measures of hepatic steatosis and liver stiffness over a 6-month treatment period.

Conditions

  • Diabete Type 2
  • Non Alcoholic Fatty Liver

Interventions

DRUG

Aspirin

Participants received 100 mg of aspirin (aspirin protect®) as oral daily doses for 6 months.

DRUG

Dapagliflozin (10Mg Tab) along with standard medical therapy

Participants received 10 mg of dapagliflozin (Diaflozimet ®) as oral once-daily doses for 6 months.

DRUG

Metformin 1000 mg

Participants received metformin 1000 mg orally once daily for 6 months.

Sponsors & Collaborators

  • Galala University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-04
Primary Completion
2025-04-05
Completion
2025-09-19

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07338331 on ClinicalTrials.gov